Exclusive

Publication

Byline

Bengaluru woman shares why Japan's 'basic civic sense' impressed her more than technology

India, March 29 -- A Bengaluru woman's reflection on her recent trip to Japan has triggered a conversation on social media about civic sense and public behaviour. The woman, Amisha Aggarwal, shared he... Read More


Pastor arrested for allegedly raping, impregnating 16-year-old girl

Nigeria, March 29 -- A pastor in Anambra State has been detained at the State Criminal Investigation Department (SCID) of the police for allegedly raping and impregnating a 16-year-old girl in the sta... Read More


Trump's pet name for Don Jr.'s ex Kimberly Guilfoyle slammed as 'disgusting' and 'inappropriate'

India, March 29 -- President Donald Trump recently revealed a pet name he uses for Kimberly Guilfoyle, the ex-fiancee of Donald Trump Jr. and current ambassador to Greece. The nickname has drawn criti... Read More


Will KKR's Matheesha Pathirana play against MI today? Shane Watson says 'It's a waiting game'

New Delhi, March 29 -- Kolkata Knight Riders (KKR) assistant coach Shane Watson said that the three-time IPL champions are waiting for an update on pacer Matheesha Pathirana, who has been recovering f... Read More


Internet shocked to learn Dhurandhar's Shirani, Bimal Oberoi, began career with Daler Mehndi: 'Baloch chief balle balle'

India, March 29 -- Aditya Dhar's Dhurandhar film 'lore' continues as the internet is shocked to learn that an actor from the film began his career with a Daler Mehndi song. Actor Bimal Oberoi, who pla... Read More


Singapore Clinical Trial: ROSETTA CRC-203: A Blinded, Randomized Phase 2/3 Study of Pumitamig in Combination with Chemotherapy Versus Bevacizumab in Combination with Chemotherapy in Participants with Previously Untreated, Unresectable, or Metastatic Colorectal Cancer

Singapore, March 29 -- The Health Sciences Authority received information related to the study titled 'ROSETTA CRC-203: A Blinded, Randomized Phase 2/3 Study of Pumitamig in Combination with Chemother... Read More


Singapore Clinical Trial: A Phase 3, Multicenter, Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Safety and Efficacy of L606 (Treprostinil Liposome Inhalation Suspension) in Participants with Pulmonary Hypertension Associated with Interstitial Lung Disease (WHO Group 3)

Singapore, March 29 -- The Health Sciences Authority received information related to the study titled 'A Phase 3, Multicenter, Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Safe... Read More


Singapore Clinical Trial: A Phase III, Randomized, Open-Label, Multicenter, Global Study of Puxitatug Samrotecan (AZD8205) Monotherapy versus Physician’s Choice of Chemotherapy in Participants with B7-H4-Selected Advanced/Metastatic Endometrial Cancer Who Progressed On or After Platinum-Based Chemotherapy and Anti-PD-1/Anti-PD-L1 Therapy (BLUESTAR-Endometrial01)

Singapore, March 29 -- The Health Sciences Authority received information related to the study titled 'A Phase III, Randomized, Open-Label, Multicenter, Global Study of Puxitatug Samrotecan (AZD8205) ... Read More


Singapore Clinical Trial: DAREON®-Lung 1: A Phase III multi-center, open-label, randomised trial of intravenous obrixtamig in combination with atezolizumab, carboplatin, and etoposide vs. atezolizumab, carboplatin, and etoposide as first-line treatment in patients with extensive-stage small cell lung cancer

Singapore, March 29 -- The Health Sciences Authority received information related to the study titled 'DAREON®-Lung 1: A Phase III multi-center, open-label, randomised trial of intravenous obrixtamig ... Read More


Singapore Clinical Trial: An open-label study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of BAY 3771249 as monotherapy or combination with other cancer treatments in participants with solid tumors harboring a KRAS G12D mutation

Singapore, March 29 -- The Health Sciences Authority received information related to the study titled 'An open-label study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and... Read More